Table 10.
Adverse events
| Parameter | Multitarget (n [%]; n = 20) | Tacrolimus8,15 (n [%]; n = 35) | MMF3,7 (n [%]; n = 43) |
|---|---|---|---|
| G-I syndrome | 2 (10.0) | 2 (5.7) | 8 (18.6) |
| Temporary GPT/GOT rise | 1 (5.0) | 3 (8.6) | 0 (0.0) |
| Transient increase in Scr | 0 (0.0) | 3 (8.6) | 0 (0.0) |
| Leucopenia | 2 (10.0) | 2 (5.7) | 1 (2.3) |
| New-onset hypertension | 3 (15.0) | 6 (17.1) | 0 (0.0) |
| Hyperglycemia | 1 (5.0) | 4 (11.4) | 0 (0.0) |
| Upper respiratory infection | 1 (5.0) | 1 (2.9) | 1 (2.3) |
| Pneumonia | 1 (5.0) | 1 (2.9) | 2 (4.7) |
| Herpes zoster or varicella | 1 (5.0) | 3 (8.6) | 2 (4.7) |
| Urinary tract infection | 1 (5.0) | 0 (0.0) | 0 (0.0) |
| Alopecia | 1 (5.0) | 5 (14.3) | 0 (0.0) |
| Irregular menstruation | 1 (5.0) | 1 (2.9) | 0 (0.0) |